Compare BridgeBio Pharma Inc (BBIO) vs Plug Power Inc (PLUG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Plug Power Inc — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B), while Plug Power Inc trades at $2.22 (market cap $2.94B). The key difference: BridgeBio Pharma Inc is far larger — about 5.6× Plug Power Inc's market cap, and BridgeBio Pharma Inc is trading nearer its 52-week high, Plug Power Inc nearer its low. Which is the better fit depends on your goals.
| BBIO | PLUG | |
|---|---|---|
Market Cap | $16.61B | $2.94B |
Sector | Health | Industrials |
52-Week High | $90.17 | $4.14 |
52-Week Low | $47.29 | $1.41 |
Enterprise Value | $18.16B | $3.73B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.
The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.
Plug Power (PLUG) trades at $2.18, up 5.31% with a bearish technical signal despite recent earnings beat. The company shows improving operational metrics with reduced cash usage and margin improvements, though it remains unprofitable with negative gross margins of -25.66%. Management targets positive EBITDA by Q4 2026 while navigating significant liquidity challenges through asset sales and financing activities.
While analyst consensus leans bullish with a $2.22 price target, PLUG faces substantial execution risks amid persistent losses and cash burn. The stock offers speculative upside if management delivers on profitability targets, but investors face elevated risk from the company's negative cash flow and competitive hydrogen market pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Plug Power Inc
Plug Power is building an end-to-end green hydrogen ecosystem—from production, storage and delivery to energy generation. The company plans to build and operate green hydrogen highways across North America and Europe. Plug will deliver its green hydrogen solutions directly to its customers and through joint venture partners into multiple end markets—including material handling, e-mobility, power generation, and industrial applications.
Read more on PLUG →
